8-K: Aptose Biosciences Enters At-the-Market Sales Agreement for Up to $1 Million

Aptose Biosciences has established an at-the-market sales facility to potentially sell up to $1 million of its common shares through A.G.P./Alliance Global Partners.

Summary

• Aptose Biosciences has entered into a sales agreement with A.G.P./Alliance Global Partners to establish an at-the-market (ATM) sales facility.
• Under this agreement, Aptose may issue and sell common shares on the Nasdaq Capital Market, with a potential aggregate offering price of up to $1,000,000.
• The company will decide the timing, price, and number of shares to be sold.
• Sales will not occur on the Toronto Stock Exchange or other Canadian markets.
• A.G.P./Alliance Global Partners will act as the agent and receive a commission of up to 3.0% of the gross sales proceeds.
• The shares will be issued under an existing registration statement filed with the SEC on October 11, 2022, and a prospectus supplement filed on February 3, 2025.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard financial transaction, which is a common practice for companies to raise capital. There are no indications of significant positive or negative implications, but the potential for dilution is a slight negative.

Positives

• The at-the-market facility provides Aptose with a flexible way to raise capital.
• The company has full control over the timing and pricing of share sales.
• The agreement is with a reputable agent, A.G.P./Alliance Global Partners.
• The shares will be sold on the Nasdaq Capital Market, a major exchange.

Negatives

• The company will incur a commission of up to 3.0% on gross sales proceeds.
• There is no guarantee that the company will be able to sell all of the shares.
• The sale of shares could dilute existing shareholders.

Risks

• The company may not be able to sell all of the shares at the desired price.
• The sale of shares could dilute existing shareholders.
• Market conditions could impact the success of the at-the-market offering.
• The company is responsible for compliance with all regulations and limitations on the number of shares that can be sold.

Future Outlook

The company may issue and sell common shares from time to time, at its discretion, through the at-the-market sales facility. The timing and amount of sales will depend on market conditions and the company's capital needs.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. This approach allows companies to sell shares gradually into the market, reducing the risk of significant price fluctuations. It is a flexible way to access capital as needed.

Comparison to Industry Standards

• The use of an at-the-market offering is a standard practice for companies like Aptose seeking to raise capital without a traditional underwritten offering.
• The commission rate of up to 3.0% is within the typical range for such agreements.
• Comparable companies in the biotech sector, such as Xencor and BioMarin, have also utilized ATM facilities to raise capital.
• The $1 million offering size is relatively small, suggesting a targeted approach to capital raising.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company will have access to additional capital to fund its operations.
• The at-the-market offering provides a flexible way to raise capital without a traditional underwritten offering.

Next Steps

• Aptose will determine the timing and amount of share sales based on market conditions and capital needs.
• A.G.P./Alliance Global Partners will execute the sales on the Nasdaq Capital Market.
• The company will continue to monitor market conditions and may issue further Placement Notices as needed.

Key Dates

Keywords

at-the-market offering, common shares, capital raise, Aptose Biosciences, A.G.P./Alliance Global Partners, Nasdaq Capital Market, sales agreement, equity financing